EUVIMEDEUVIMED entdecken
Crossref

Presence of Gut Microbiota Worsens D‐Galactosamine and Lipopolysaccharide‐Induced Hepatic Injury in Mice

Kazuma Ohshima, Satoru Torii iD, Shigeomi Shimizu iD

Genes to Cells · 2025

DOI: 10.1111/gtc.13183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes to Cells, 2025. Verfasst von Kazuma Ohshima und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathological Cell Biology, Advanced Research Initiative, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Galactosamine, Gastrointestinal Microbiome, Lipopolysaccharides, Polymyxin B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: JSPS KAKENHI Grant-in-Aid for Scientific Research, MEXT KAKENHI Grant-in-Aid for Scientific Research on Innovative Areas, AMED-CREST.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute liver failure is a serious, life‐threatening disease. Although the gut microbiota has been considered to play a role in liver failure, the extent to which it is involved in the pathogenesis of this disease has not been fully elucidated to date. Therefore, we here analyzed the importance of the presence of intestinal microbiota in the pathogenesis of acute liver injury, using D‐galactosamine (D‐GalN)/lipopolysaccharide (LPS)‐treated mice, which is a widely used experimental model of acute liver injury. First, administration of the antibiotic polymyxin B markedly alleviated liver injury. Liver injury was also reduced in germ‐free mice, leading to the conclusion that the presence of intestinal microbiota aggravates D‐GalN/LPS‐induced liver injury. The amount of bacteria and LPS transferred from the gut to the blood was not increased by D‐GalN/LPS, suggesting that the worsening of liver injury was not simply owing to the entry of bacteria into the circulation. In conclusion, acute liver injury in polymyxin B‐pretreated or germ‐free mice was ameliorated by modulation of the gut microbiota. Modification of the gut microbiota using polymyxin B may hence have the potential to alleviate acute liver injury in human patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GalactosamineGastrointestinal MicrobiomeLipopolysaccharidesPolymyxin BChemical and Drug Induced Liver InjuryAnimalsMiceMaleMice, Inbred C57BLLiverDisease Models, AnimalAnti-Bacterial AgentsLiver Failure, Acute

Stichwörter der Autor:innen

D‐galactosamineLPSacute liver injurygerm‐freepolymyxin B

Substanzen

GalactosamineLipopolysaccharidesPolymyxin BAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pathological Cell Biology, Advanced Research Initiative, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Satoru Torii, Shigeomi Shimizu

Förderung

  • JSPS KAKENHI Grant-in-Aid for Scientific Research
  • MEXT KAKENHI Grant-in-Aid for Scientific Research on Innovative Areas
  • AMED-CREST
  • AMED, Project for Psychiatric and Neurological Disorders
  • Joint Usage/Research Program of Medical Research Institute
  • Tokyo Medical and Dental University
  • Japan Agency for Medical Research and Development

Zitieren

APA

Ohshima, K., Torii, S., & Shimizu, S. (2025). Presence of Gut Microbiota Worsens D‐Galactosamine and Lipopolysaccharide‐Induced Hepatic Injury in Mice. Genes to Cells. https://doi.org/10.1111/gtc.13183

Vancouver

Ohshima K, Torii S, Shimizu S. Presence of Gut Microbiota Worsens D‐Galactosamine and Lipopolysaccharide‐Induced Hepatic Injury in Mice. Genes to Cells. 2025. doi:10.1111/gtc.13183

BibTeX
@article{Ohshima2025,
  author = {Ohshima, Kazuma and Torii, Satoru and Shimizu, Shigeomi},
  title = {Presence of Gut Microbiota Worsens D‐Galactosamine and Lipopolysaccharide‐Induced Hepatic Injury in Mice},
  journal = {Genes to Cells},
  year = {2025},
  doi = {10.1111/gtc.13183}
}
Kostenlos starten →